ESMO 2024 Highlights: Presenter Vignette – Lorenza Rimassa

ESMO 2024 Highlights: Presenter Vignettes

Lorenza Rimassa

MD

Humanitas Cancer Center

Abstract# 947MO

Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

© All rights reserved

Made with ❤ by Elementor

Oncology Career Hub
Post A Job
Scientific Steering Committee
Events

About Us
Contact Us
Disclaimer
MDBriefcase

199 Bay Street #4000
Toronto, ON M5L 1A9

Twitter Instagram Facebook-f Linkedin-in

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Tumour Sites
- Breast
- Colorectal
- GI
- GU
- Gynecology
- Hematology
- Lung
- Melanoma
- Sarcoma
- Other Topics
Events
Oncology Career Hub
- View Openings
- Post A Job
About Us

Search for:

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. See our privacy policy and cookie policy.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!